Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?

ABSTRACT:

Introduction

Treatments for subjects with Covid-19 are required. One approach is neutralizing monoclonal antibodies. Bamlanivimab and etesevimab are monoclonal antibodies to SARS-CoV-2.

Areas covered

This evaluation is of the phase 3 BLAZE-1 clinical trial, which was of bamlanivimab plus etesevimab in adult ambulatory participants with a risk factor for, and mild to moderate, Covid-19 illness. The primary outcome was Covid 19 related hospitalization of ≥ 24 hours or death from any cause by day 29, and this occurred in 2.1% subjects in the bamlanivimab/etesevimab group, compared to 7.0% in the placebo group.

Expert opinion

In the pandemic, the attempts by the FDA to shorten approval processes for medicines and by journals to make information available in a timely manne

SUBMITTER: Doggrell SA 

PROVIDER: S-EPMC8500303 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature